z-logo
Premium
The pharmacokinetics of γ‐glutamyl‐ l ‐dopa in normal and anephric rats and rats with glycerol‐induced acute renal failure
Author(s) -
Boateng Yaw A.,
Barber Harold E.,
MacDonald Thomas M.,
Petrie James C.,
Lee Michael R.,
Whiting Paul H.
Publication year - 1990
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1990.tb12705.x
Subject(s) - pharmacokinetics , metabolite , volume of distribution , elimination rate constant , metabolism , chemistry , endocrinology , medicine , pharmacology , active metabolite , kidney , half life
1 The pharmacokinetics of γ‐glutamyl‐ l ‐dopa (gludopa) and its metabolite, l ‐dopa, have been studied in normal rats at three dose levels of gludopa: 2 mg kg −1 , 5 mg kg −1 and 7.5 mg kg −1 . The extent of metabolism in normal rats, and the pharmacokinetics in anephric rats and rats with glycerol‐induced acute renal failure (ARF) were also studied at a gludopa dose of 2 mg kg −1 . 2 Gludopa was extensively metabolised to l ‐dopa with only about 10% of an injected dose being excreted unchanged. Normal rats had a rapid gludopa clearance of 50.9 ± 9.6 ml min −1 kg −1 and elimination rate constant of 2.99 ± 0.27 h −1 . The mean residence time and half‐life were 20.9 ± 1.4 and 14.4 ± 1.0 min, respectively. The apparent volume of distribution at steady state was 1.05 ± 0.181 kg −1 . 3 No statistically significant differences were found in the main pharmacokinetic parameters between ARF and controls for either gludopa or its metabolite l ‐dopa. 4 In anephric rats and controls the kidneys were found to contribute about 68.5% and 67.2% to the elimination of gludopa and the metabolite l ‐dopa, respectively. 5 These results confirm that gludopa is an efficient pro‐drug for l ‐dopa, and that the kidneys are the major site of gludopa metabolism. It seems likely that the renal specificity of gludopa persists in ARF.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here